NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease

Movement Disorders

Volumn 25, Issue 4, 2010, Pages 508-510

  Varanese, Sara ^a,b   Howard, Jonathan ^a   Di Rocco, Alessandro ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ENTACAPONE; LEVODOPA; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADULT; AGED; CASE REPORT; CHOREA; CLINICAL EVALUATION; COGNITION; CONVALESCENCE; DETERIORATION; DISEASE DURATION; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; LETTER; LIVEDO RETICULARIS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SCORING SYSTEM; VISUAL HALLUCINATION;

AGED; ANTIPARKINSON AGENTS; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; INCIDENCE; LEVODOPA; MALE; MEMANTINE; N-METHYLASPARTATE; PARKINSON DISEASE;

EID: 77949495194     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22917     Document Type: Letter

References (12)

1. Chase TN, OhJD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000;47:S122-S129.
2. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 1989;166:591-592.
3. Schneider E, Fisher PA, Clemens R, Balzereit F, Funfgeld EW, Haase HJ. Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study. Disch Med Wochenschr 1984;109:987-990.
4. Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992;4:277-282.
5. Hanagasi HA, Kaptanoglu G, Sahin HA, Emre M. The use of NMDA antagonist memantine in drug-resitant dyskinesia resulting from L-dopa. Mov Disord 2000;15:1016-1017.
6. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999;22:273-276.
7. Fahn S, Elton RL. Members of the Unified Parkinson's Disease Rating Scale Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent development in Parkinson's disease, Vol. 2. Florham Park, NJ: Mcmillan Healthcare Information; 1987. p 153-164.
8. Spanagel R, Eilbacher B, Wilke R. Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat - a pharmachokinetic microdyalis study. Eur J Pharmacol 1994; 262:21-26.
9. Lupp A, Lucking CH, Koch R, Jaskisch R, Feuerstein TJ. Inhibitory effects of the antiparkinsonian drug memaninte and amantadine on N-methyl-D-aspartate- evoked acetylcholinie release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 1992;263:717-724.
10. Buhmann C, Gorsler A, Bäumer T, et al. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease. Brain 2004;127:2732-2746.
11. Sabatini U, Boulanouar K, Fabre N, et al. Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain 2000;123:393-403.
12. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 2007;53:699-723.